Japanese Equity Specialist, Ortus Advisors

Andrew Jackson

Japanese Equity Specialist

Ortus Advisors

Thematic (Sector/Industry)

<ul>
<li>Nidec faces damning data falsification allegations with over 1000 cases of quality tampering across household appliances and auto components.</li>
<li>Olympus beats on strong endoscope sales and improved margins with high short interest and a buyback this morning.</li>
<li>Japan's SPE names likely to take a beating today after fading off strong opens for several days.</li>
</ul>


Nidec faces damning data falsification allegations with over 1000 cases of quality tampering across household appliances and auto components.
Olympus beats on strong endoscope sales and improved margins with high short interest and a buyback this morning.
Japan's SPE names likely to take a beating today after fading off strong opens for several days.


Japan Morning Connection: Nidec Faces a Damning Scandal While Olympus Is Primed for a Squeeze

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Shanghai Henlius Biotech announced that PMDA of Japan approved phase 2/3 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) for advanced squamous non-small cell lung cancer (NSCLC).</li>
<li>Simcere Pharmaceutical announced that, SIM0613 for Injection, an antibody-drug conjugate, received the clinical trial approval in China, and is intended for commencing the clinical trial for advanced solid tumors.</li>
<li>Olympus has signed an exclusive global distribution agreement with EndoRobotics. Under this agreement, robot-assisted technologies manufactured by EndoRobotics will be distributed globally by Olympus exclusively.</li>
</ul>


Shanghai Henlius Biotech announced that PMDA of Japan approved phase 2/3 clinical trial of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) for advanced squamous non-small cell lung cancer (NSCLC).
Simcere Pharmaceutical announced that, SIM0613 for Injection, an antibody-drug conjugate, received the clinical trial approval in China, and is intended for commencing the clinical trial for advanced solid tumors.
Olympus has signed an exclusive global distribution agreement with EndoRobotics. Under this agreement, robot-assisted technologies manufactured by EndoRobotics will be distributed globally by Olympus exclusively.


APAC Healthcare Weekly (May 10) – Henlius Bio, Simcere, Olympus, Daewoong Pharma

Japan Specialist

Mark Chadwick

<ul>
<li>Japanese equities traded broadly flat this week, with performance shaped by sector rotation rather than index direction.</li>
<li>Investors rotated decisively into “hardware” and national security–linked sectors, reflecting policy signals from Prime Minister Sanae Takaichi</li>
<li>GS Yuasa was the top performer this week, after the company announced plans to build a new lithium-ion battery plant for energy storage systems</li>
</ul>


Japanese equities traded broadly flat this week, with performance shaped by sector rotation rather than index direction.
Investors rotated decisively into “hardware” and national security–linked sectors, reflecting policy signals from Prime Minister Sanae Takaichi
GS Yuasa was the top performer this week, after the company announced plans to build a new lithium-ion battery plant for energy storage systems


Japan Strategy Weekly | From Austerity to Strategic Investment

<ul>
<li>Sandisk +15% as the NAND S/D imbalance shows no signs of easing until next year at least.</li>
<li>Olympus's new CEO steps into his role by announcing 2,000 job cuts which the market will like.</li>
<li>Rohm throwing cold water on its AI ambitions makes this a soon to be consensus short for now.</li>
</ul>


Sandisk +15% as the NAND S/D imbalance shows no signs of easing until next year at least.
Olympus's new CEO steps into his role by announcing 2,000 job cuts which the market will like.
Rohm throwing cold water on its AI ambitions makes this a soon to be consensus short for now.


Japan Morning Connection: Fridays Tape Closed Down but a Big Rally off the Intraday Lows

<ul>
<li>Takeda has dropped AstraZeneca-partnered antibody drug candidate from its pipeline. Eisai and Merck are closing late-stage trial of Lenvima plus Keytruda in hepatocellular carcinoma on disappointing result.</li>
<li>Wuxi AppTec sharpens CRDMO business by selling its China-based clinical research subsidiaries. FDA has designated Celltrion’s Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.</li>
<li>CSL is delaying demerger of CSL Seqirus ‘to maximise shareholder value.’ PharmaEssentia has filed for the additional indication of Besremi for Essential Thrombocythemia (ET) with the FDA.</li>
</ul>


Takeda has dropped AstraZeneca-partnered antibody drug candidate from its pipeline. Eisai and Merck are closing late-stage trial of Lenvima plus Keytruda in hepatocellular carcinoma on disappointing result.
Wuxi AppTec sharpens CRDMO business by selling its China-based clinical research subsidiaries. FDA has designated Celltrion’s Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.
CSL is delaying demerger of CSL Seqirus ‘to maximise shareholder value.’ PharmaEssentia has filed for the additional indication of Besremi for Essential Thrombocythemia (ET) with the FDA.


APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia

Japan

OLYMPUS CORPORATION manufactures optoelectronic products. The Company's products include cameras, video sets, endoscopes for medicine and industrial use, microscopes, analytical equipment, office communication systems, and laseroptical scanners.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Olympus (7733 JT)

Japan Morning Connection: Nidec Faces a Damning Scandal While Olympus Is Primed for a Squeeze

Nidec accused of data falsification, Olympus sees success with endoscope sales and better margins, Japan's SPE stocks expected to decline.

Andrew Jackson

APAC Healthcare Weekly (May 10) – Henlius Bio, Simcere, Olympus, Daewoong Pharma

Henlius Bio and Simcere got trial approval for their respective ADC candidates in Japan and China, respectively. Olympus forges exclusive global...

Tina Banerjee

Japan Strategy Weekly | From Austerity to Strategic Investment

Japanese equities traded flat this week, driven by sector rotation rather than index direction. Investors favored "hardware" and national security...

Mark Chadwick

Japan Morning Connection: Fridays Tape Closed Down but a Big Rally off the Intraday Lows

Olympus will be in play today after earnings highlight it as a restructuring play. Rohm looks like a short vs long with Fuji Elec.

Andrew Jackson

APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia

Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus....

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Japan Morning Connection: Nidec Faces a Damning Scandal While Olympus Is Primed for a Squeeze

​Nidec accused of data falsification, Olympus sees success with endoscope sales and better margins, Japan's SPE stocks expected to decline.

Andrew Jackson

APAC Healthcare Weekly (May 10) – Henlius Bio, Simcere, Olympus, Daewoong Pharma

Henlius Bio and Simcere got trial approval for their respective ADC candidates in Japan and China, respectively. Olympus forges exclusive global...

Tina Banerjee

Japan Strategy Weekly | From Austerity to Strategic Investment

​Japanese equities traded flat this week, driven by sector rotation rather than index direction. Investors favored "hardware" and national security...

Mark Chadwick

Japan Morning Connection: Fridays Tape Closed Down but a Big Rally off the Intraday Lows

Olympus will be in play today after earnings highlight it as a restructuring play. Rohm looks like a short vs long with Fuji Elec.

Andrew Jackson

APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia

Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus....

Tina Banerjee

Nidec accused of data falsification, Olympus sees success with endoscope sales and better margins, Japan's SPE stocks expected to decline.

Japanese equities traded flat this week, driven by sector rotation rather than index direction. Investors favored "hardware" and national security...